MarketSmith should now be evaluated through IBD's MarketSurge product family: a premium growth-stock research workflow built around IBD ratings, screens and CAN SLIM-style chart analysis. It is not a broker, journal, options-flow terminal or general scanner. Its value depends on whether the investor actually follows the IBD growth-stock process.
This review was refreshed on July 21, 2026 against current IBD product and MarketSurge pages. Older references to a fixed MarketSmith trial structure were removed because IBD's introductory offers change and the current public materials emphasize MarketSurge Premium at renewal.
What MarketSmith / MarketSurge is trying to solve
The product exists for investors who want a structured growth-stock research process: earnings strength, relative strength, industry group leadership, institutional sponsorship, chart bases and buy-zone discipline. That is a very specific workflow. It can be powerful for the right user and frustrating for anyone who wants a broad all-purpose trading platform.
IBD's current MarketSurge page positions the product as professional-grade research for individual investors with premium features included. The broader IBD products page shows MarketSurge Premium renewing at $149.95/month after the initial offer period.
The price only makes sense if the methodology is used
At $149.95/month renewal pricing, this is a serious subscription. It should not be bought casually as another watchlist tool. A buyer should already want IBD's ranking logic, stock lists, charts, pattern workflow and research cadence.
If the trader wants cheap screening, compare Finviz, Stock Rover and TradingView. If they want intraday alerts or options flow, compare stock screeners and options-flow tools. MarketSurge is most defensible when the user will actually run the IBD process, not when they just want more charts.
Strengths for growth investors
The strongest use case is narrowing a large market into growth candidates with strong relative strength, earnings support and recognizable bases. That helps investors avoid random ticker browsing and forces a repeatable research checklist.
Pattern recognition and curated lists are useful as a starting point, but they do not remove judgment. A detected base still needs market context, volume analysis, risk planning and sell rules. The software can organize the process; it cannot guarantee that a breakout will work.
Where it is a poor fit
MarketSurge is a poor fit for traders focused on futures, forex, crypto bots, prop-firm execution, broker sync or trade journaling. It also may be overkill for buy-and-hold investors who only need allocation, valuation and portfolio monitoring.
Because the product is methodology-heavy, there is a learning curve. A user who does not understand IBD's terminology may spend the trial learning the language rather than deciding whether the workflow improves decisions.
MarketSmith versus general stock screeners
General screeners are better when the trader wants flexible filters across many strategies. MarketSurge is better when the investor wants an opinionated growth-stock workflow. That distinction matters for ranking fairness: a flexible screener can have more knobs, while MarketSurge can still be better for a CAN SLIM investor.
The right test is one weekend research session. Build a watchlist, inspect the top candidates, write entry and invalidation rules, then compare whether MarketSurge produced a more disciplined list than a generic screener.
Our current assessment
MarketSmith/MarketSurge remains a premium specialist product. It deserves a high score for growth-stock research depth and a lower value score for users outside that methodology. The monthly renewal price demands actual process fit.
Choose it if IBD-style growth investing is your operating system. Choose a cheaper screener or charting platform if you only need filters, alerts or charts.